Short-Term Effects of Microglia-Specific Mitochondrial Dysfunction on Amyloidosis in Transgenic Models of Alzheimer's Disease

Johannes Steffen, Jan Stenzel, Saleh Ibrahim, Jens Pahnke*

*Corresponding author for this work
7 Citations (Scopus)

Abstract

Reduction of mitochondrial activity is a subtle and early event in the pathogenesis of Alzheimer's disease. Mitochondrial damage and consequentially enhanced production of reactive oxygen species is particularly occurring in the vicinity of amyloid plaques. Since all cells are affected by mitochondrial damage, analyses of cell type-specific effects are challenging. To study the impact of mitochondrial alterations on microglial activity in a homogeneous genetic background, we generated bone marrowchimeras of irradiated 46-days-old APP-transgenic mice. For reconstitution, bone marrowfrom CX3CR1-eGFP mice with mitochondria of either non-obese diabetic or C57BL/6J animals was utilized. Successful reconstitution was evident in 100-day-old animals, by the presence of eGFP-positive cells in liver and spleen. In the brain, one-third of IBA1-positive microglia cells were newly recruited eGFP-expressing cells. Although donor-derived microglia were equally located in the proximity of amyloid plaques, no difference was observed in either the amyloid level, total number, or microglial coverage of plaques. These results indicate that during this brief and early phase of amyloid deposition, beneficial mitochondrial alterations in the newly recruited third of microglial cells were not sufficient to affect the amyloidosis in APP-transgenic mice.

Original languageEnglish
JournalJournal of Alzheimer's Disease
Volume65
Issue number2
Pages (from-to)465-474
Number of pages10
ISSN1387-2877
DOIs
Publication statusPublished - 2018

Funding

The experiments were performed at the University of Rostock / Department of Neurology and financed by the intramural grant of the University of Rostock (FORUN 889012) to Ja.S. We thank Thomas Brüning for technical support with histology and Gerda Brüsch for help with animals. The work of J.P. is/was supported by the following grants: Deutsche Forschungsgemeinschaft/ Germany (DFG PA930/9, DFG PA930/12); Leibniz Society/ Germany (SAW-2015-IPB-2); HelseSØ/ Norway (2016062); Norsk forskningsrådet/ Norway (247179, 251290, 260786); Horizon 2020/ European Union (643417 (PROP-AD)). NeuroGeM is an EU Joint Programme - Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the aegis of JPND - www.jpnd.eu (CIHR – Canada, BMBF – Germany, NRF #247179 – Norway, ZonMW – The Netherlands). PROP-AD is an EU Joint Programme - Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the aegis of JPND - www.jpnd.eu (AKA #301228 – Finland, BMBF #01ED1605-Germany, CSO-MOH #30000-12631 - Israel, NFR #260786 - Norway, SRC #2015-06795 - Sweden). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement #643417 (JPco-fuND).

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Fingerprint

Dive into the research topics of 'Short-Term Effects of Microglia-Specific Mitochondrial Dysfunction on Amyloidosis in Transgenic Models of Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this